
    
      American Medical Systems, Inc. (AMS) hypothesized that the original treatment pattern used to
      support a previous FDA approval for the Her OptionÂ® Cryoablation Therapy System for Treatment
      of abnormal uterine bleeding was not optimal and that extended freeze regimens will result in
      improved outcomes for patients.
    
  